A 2025 meta-analysis in non–small-cell lung cancer (NSCLC) indicates glucocorticoid administration is significantly associated with worse progression-free survival (PFS) and overall survival (OS) for patients on ICIs. WJAMS [Internet]. 2025 Nov. 21 [cited 2026 Mar. 23];2(11):1-3. Available from: https://wasrpublication.com/index.php/wjams/article/view/176